Sarcoma (Jan 1999)

Lack of Activity of Docetaxel in Soft Tissue Sarcomas: Results of a Phase II Study of the Italian Group on Rare Tumors

  • Armando Santoro,
  • Antonella Romanini,
  • Alberto Rosso,
  • Sergio Frustaci,
  • Alessandro Comandone,
  • Gaetano Apice,
  • Domenico De Toma,
  • Luigi Dogliotti,
  • Rita Lionetto,
  • Carla Dani,
  • Paolo Bruzzi,
  • Marco Piolini,
  • Paola Bergnolo,
  • Claudio Verusio

DOI
https://doi.org/10.1080/13577149977613
Journal volume & issue
Vol. 3, no. 3-4
pp. 177 – 181

Abstract

Read online

Purpose. The prognosis of advanced soft tissue sarcoma is poor, only a few drugs showing some activity with response rates around 15– 25%. Consequently drug development seems mandatory to improve treatment outcome. Following previous favourable EORTC experience, the Italian Group on Rare Tumors started a phase II study with docetaxel to confirm the activity of this drug in soft tissue sarcoma.